Follow-up study for prior trial participants
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study invites people who already took part in the Steno780G study to join a follow-up to see how they are doing over time. Participation may help researchers learn more about long-term effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in the Steno780G study before
- You are willing and able to follow the study procedures as determined by the study doctor
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the Medtronic 780G insulin pump helps people with type 1 diabetes and gastroparesis (slowed stomach emptying) control their blood sugar better than their usual care. It requires continuous glucose monitoring and certain blood sugar levels.
This trial studies how the Medtronic 780G “closed-loop” insulin system works for young people with type 1 diabetes. It may help by improving how automatically insulin is delivered, depending on your body’s needs.
This study looks at how well your blood sugar stays in the target range and whether it's linked to the health of your blood vessels and heart. You would use a continuous glucose monitor, and the results may help improve care for people with type 1 diabetes.
This study tests a new automated insulin delivery system to help people with type 1 diabetes better manage their blood sugar. It aims to see if the system improves glucose control safely.
This study tests a new extended-wear sensor that helps track glucose levels continuously. It is designed to see if a next-generation sensor is accurate and safe for people with diabetes.
This study looks at how timing your insulin bolus (the extra insulin you take with meals) can improve blood sugar control. It involves adults with type 1 diabetes who are already using the MiniMed 780G pump with Novorapid insulin.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.